CHEK1 and urinary bladder carcinoma: Importantly, although ATR-Chk1 signaling components have been developed as therapeutic targets and the associated inhibitors are currently being entered into clinical trials for evaluation [27], a role for ATR in the progression of bladder cancer remains unknown as well as the exact mechanism by which ATR-Chk1 pathway affects the response to cisplatin.